The results, according to the study, were promising, as the researchers found an immune response resulting from the vaccine in all patients, which could "last for years."

The vaccine stimulates the immune system to create anti-tumor T cells, which are an important type of white blood cell that helps the immune system to develop long-term immunity against inflammatory and autoimmune diseases.

Despite the promising results of the study, it is not conclusive evidence that cancer vaccines will work in everyone who suffers from skin cancer or other cancers.

The study sample size of only eight people is too small to allow any final conclusion about the effectiveness of the vaccine on a large scale.

The team is now looking to make changes to vaccines to test them on a variety of patients with different tumors and at different stages of the disease.

It will take at least "a few years" for "personal vaccines" to be used; Researchers have yet to overcome several challenges, including time and cost.